FindTrial
Sign In

Study of Advanced Cancer Treatment on Head & Neck Cancer patients and Breast Cancer patients

Advancing Cancer-care through CANScriptTMEnabled Personalized Treatment(ACCEPT): A non-randomized, investigator initiated, observational trial to measure predictive power of CANScriptTM for chemotherapeutics and targeted therapy in patients with newly diagnosed, locally advanced head & neck cancer and refractory / relapsed triple negative breast cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/05/013727
Enrollment
260
Registered
2018-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Newly diagnosed, locally advanced Head & Neck Cancer and refractory / relapsed triple negative breast cancer patients

Interventions

Intervention1: NA: NA Control Intervention1: NA: NA

Sponsors

Tata Memorial Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with locally advanced H&N Ca requiring neo-adjuvant therapy, aged 18-75 are eligible for the ACCEPT-H&N trial. 2.Patients from whom at least 100-200 mm3 non-necrotic tumor can be obtained by biopsy or surgery. 3.ECOG Performance Status of 0 â?? 1

Exclusion criteria

Exclusion criteria: 1.Any other concurrent disease or illness, which in the judgment of the investigator would make the subject inappropriate for entry into the study

Design outcomes

Primary

MeasureTime frame
1.To evaluate the predictive power of CANScriptTM by comparing CANScriptTM outcomes to clinical outcomes at the end of 2/3 cycles of chemotherapy in H&N cancer and TNBC patients.Timepoint: After completion of treatment—

Secondary

MeasureTime frame
1.To evaluate the predictive power of CANScriptTMby comparing CANScriptTM outcome to patientâ??s progression free survival and overall survival when followed for a period of 2 years from study enrollment to disease progression or death (whichever is earlier).Timepoint: After completion of treatment—

Countries

India

Contacts

Public ContactDr Shripad Banavali

Tata Memorial Hospital

banavali_2000@yahoo.com02224177217

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026